Amneal receives EU approval for omalizumab biosimilar
Amneal Pharmaceuticals (AMRX) received EU approval for Adcomfo, a biosimilar to XOLAIR. The approval covers treatments for severe allergic asthma, chronic rhinosinusitis, and chronic urticaria. Adcomfo was developed by Kashiv BioSciences, acquired by Amneal in August. The product is supported by clinical data and is marketed in Europe by ADVANZ PHARMA. AMRX's U.S. application is under FDA review.
How this was made
The 30-second read
Why it matters
This is a regulatory de-risking event for AMRX’s biosimilar program in Europe, while U.S. commercialization remains contingent on FDA approval of its BLA.
Market read
Traders may reassess AMRX’s biosimilar probability-weighting and commercialization outlook after a fresh EU authorization, even as U.S. remains pending.
What to watch
The article notes ADVANZ Pharma holds EU commercialization rights and that the U.S. FDA BLA is still under review, so the biggest upside may depend on U.S. timing and partner economics rather than EU alone.
Background
Amneal’s Adcomfo is a biosimilar to XOLAIR (omalizumab) developed via collaboration and acquired through Kashiv BioSciences, with EU approvals already progressing.
Ticker impact
Amneal says the European Commission granted marketing authorization for its omalizumab biosimilar Adcomfo (Adcomfo), expanding EU commercial availability.
Likely positive bias as the market prices in improved probability of EU uptake and progress toward the still-pending U.S. approval.
The article is a first-report regulatory approval in Europe for AMRX’s biosimilar, with defined indications, formulations, and a stated FDA BLA still under review, which typically improves forward commercialization expectations.
Market effects
Adds incremental competitive pressure in omalizumab biosimilars in Europe and reinforces the broader biosimilar approval pipeline narrative.
EU approval can shift payer and formulary dynamics for severe allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria.
Supports global read-through for biosimilar timelines, especially as the U.S. FDA BLA is still pending.
Counterpoint
EU approval may not translate quickly into material revenue if uptake is slow, pricing is pressured, or ADVANZ Pharma’s commercialization execution limits near-term impact.
Key entities
- companyAmneal Pharmaceuticals
NASDAQ-listed company receiving EU marketing authorization for its omalizumab biosimilar Adcomfo.
- productAdcomfo (omalizumab)
Amneal’s biosimilar to XOLAIR, approved for multiple add-on indications in Europe.
- regulatorEuropean Commission
Granted marketing authorization for Adcomfo following a positive CHMP opinion.
- partnerADVANZ PHARMA
Holds EU marketing authorization and regional commercialization rights through partnership with Alvotech.
- regulatorU.S. FDA
BLA for Amneal’s proposed biosimilar to XOLAIR is currently under review.

